Ulcerative Colitis Therapeutics Market: New Business Opportunities & Investment Research Report 2019

A new market research report by Transparency Market Research, titled “Ulcerative Colitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” presents an extensive analysis of the market. The report helps in identifying the major trends driving and shaping the growth of the market. The study also encapsulates the competitive landscape and presents valuable insights on the pipeline products in the market for ulcerative colitis therapeutics market. A review has been provided on the micro and macro factors benefiting the existing players and the upcoming players in the market. The report helps in understanding and identifying the diverse and important kinds of therapeutics still under development to treat ulcerative colitis.

The report starts by providing the definition and symptoms of ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease causing ulcers and inflammation in the colon, the biggest part of the large intestine, either partially or completely. The prime symptom of an active disease includes diarrhea and blood. This disease can sometimes result in life-threatening complications owing to the fact that it is a result of the abnormal response of the immune system. It is primarily prevalent in the age group ranging from 15 to 30 years. As per the report, at present there is no known cure for this disease; however, the launch of new therapeutics may offer symptomatic treatment options.

In terms of drug class, the report segments the market for ulcerative colitis therapeutics into aminosalicylates, corticosteroids, immune modulators, antibiotics, and others. The segment of aminosalicylates is further segmented into sulfasalazine, balsalazide, and mesalamine. The segment of corticosteroids is further segmented into prednisone and methylprednisolone while the segment of antibiotics is further segmented into ciprofloxacin and ampicillin. Factors such as the high sales of the already existing drugs and the strong pipeline of therapeutic products will stimulate the growth of the market.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2185

The report states that some of the recently launched FDA-approved drugs for the treatment of ulcerative colitis include SIMPONI ARIA, an infusion treatment by Janssen Biotech, Inc. This drug was launched in July 2013. Santarus Inc. launched UCERIS in January 2013 while Warner Chilcott introduced DELZICOL in April 2013.

In terms of geography, the report segments the market into Asia Pacific, North America, Europe, and Rest of the World (RoW). North America, Northern Europe, and the UK have reported the highest ulcerative colitis cases in the past few years, as per the U.S Pharmacist. As stated in the report, the key manufacturers operating in the market are Johnson & Johnson, Takeda Pharmaceutical Company, Janssen Biotech, Inc., Abbott Laboratories, and Pfizer Inc., among others.

Protein Therapeutics Market Set to Expand by 2019

Proteins are essential for good health; people affected by genetic disorders cannot produce these proteins. Examples of such proteins include insulin, various blood clotting factors, growth hormones and others. Protein therapy ensures efficient administration of these proteins to patients suffering from deficiency, resulting in effective therapeutic benefits. It is a type of medical treatment that possesses therapeutic effects in many diseases such as diabetes, brain diseases and cancer. Protein therapeutics are classified functionally into five major groups-

• Group I: Protein therapeutics with enzymatic or regulatory activity
• Group II: Protein therapeutics with special targeting activity
• Group III: Protein vaccines
• Group IV: Protein diagnostics

The protein therapeutics market presents immense potential due to its untapped market potential and wide range of application areas. More than 100 modified therapeutic proteins have been approved for clinical use in the U.S. and European Union. At present there are various protein therapeutics in development based on their pharmacological activity, molecular mechanism of activity and their molecular types.

For Technological breakthroughs, Value chain and stakeholder analysis Get Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2035

The protein therapeutics market can also be segmented based on product type, indication areas and geographies. The product segment includes monoclonal antibodies (mAbs), insulin, interferon, blood clotting factors and others. The various indication areas include diabetes, cancer, neurological disorders, genetic disorders and other indications. The major factors driving the protein therapeutics market are the increasing incidence of various chronic disorders such as cardiovascular, cancer and diabetes etc. and enhanced investments for the development of novel and efficient drugs. Moreover, rising number of medical insurance services and increased outsourcing of drug development processes are also expected to boost market growth. Increased awareness and high efficiency of these therapeutics with minimal side effects results in high acceptance levels by the end users. The major challenges of this market refer to the development of efficient methodologies to study the complex biological systems, catering to the individual variations and others including resistance to therapy and ensuring target efficiency.

Patent expirations of top selling protein therapeutics may mask the growth of the market. Some of the leading manufacturers of protein therapeutics are Roche Group, Sanofi, Eli Lilly & Company, Johnson & Johnson, Novartis, Bristol Myers Squibb Co., Pfizer, Inc., Amgen, Inc., and Merck Sereno S.A.

Synthetic Blood Substitutes Market Outlook to 2019 Latest Industry Forecast Report

The primary use of the blood substitute is to provide a temporary support to the circulation system whenever the conditions demand. These conditions may be blood transfusions or surgeries in which blood substitutes are mostly focused on the basic role of transporting the oxygen for a short duration. There various blood substitutes available such as Perflurocarbons (PFC) emulsions and Hemoglobin-based oxygen carriers. The Perflurocarbons are derived from a group of hydrocarbons in which the hydrogen atoms are replaced by fluorine atoms and has been beneficial in creation of artificial blood during surgeries.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2005

The most common PFCs are the Perfluorodecalin and Perflubron. The major advantage of PFCs is they permit easy transportation of the oxygen to the body. However, the common side effects cited by use of these PFCs are decrease in the blood platelet counts and causes flu-like symptoms in the patients. While, the hemoglobin based oxygen carriers have been successfully being used to mimic the role of oxygen carrier role of hemoglobin in the body. Since, this substitute has been available in much larger quantities, can be stored for a longer duration and can be sterilized makes it a more preferred choice by the physicians. The chief problems associated with synthetic blood substitutes are anaphylactic shock especially in patients who are frequent users of these substitutes. Despite, significant research there has still a huge gap in meeting these safety requirements. Companies are now focusing towards introduction of innovative biotechnological techniques to introduce an effective blood substitute. The company OPK Biotech, managed to successfully develop hemoglobin-oxygen based carrier through chemical stabilization of bovine hemoglobin. This flagship product named “Hemopure” has been approved and sold in South Africa since past several years. Moreover, the U.S. Armed Services has also been conducting research since Vietnam War which has helped them to introduce substitutes such as dried powder that can be stored, packed and transported and then reconstituted as liquid prior to transfusion.

Read Full Report: http://www.transparencymarketresearch.com/synthetic-blood-substitutes.html

Some of the major driving factors for growth of this market are rise in the number of trauma cases including burns, road accidents and military wars. In addition, a plummeted rise in the geriatric population has led to seeking various surgical interventions such as blood cancer treatment, cardiac surgeries and others which has consequently led to a strong demand for artificial blood substitutes.Geographically, the North America accounts for the largest market for artificial synthetic blood substitutes market followed by Europe. Some of the major players of this market includes Biopure (Hemopure), Northfield (Polyheme), Sangart and Dendritech.

Surgical Equipment Market - Worldwide Market Shares, Strategies, and Forecasts 2013 to 2019

According to a market research report published by Transparency Market Research, the global surgical equipment market is estimated to expand at a CAGR of 4.2% during the period between 2013 and 2019. The report, titled “Surgical Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” projects the global surgical equipment market to be worth US$11.28 bn by 2019. The overall market stood at a valuation of US$8.43 bn in 2013.

Surgical equipment are widely used during surgical procedures for making incisions, grasping certain tissue or skin, holding organs and tissue back, coagulation of blood vessels, providing access to site of operation, and closing the wound by stapling or stitching. Handheld instruments, staples, sutures, and electrosurgical devices are the most commonly used surgical equipment.

The report states that the year-on-year rise in the number of surgical procedures and the growing demand for minimally invasive procedures have fuelled demand from the global surgical equipment market. The rapidly increasing geriatric population and various technical advancements have also augmented the growth of the market.

However, the growing demand for advanced wound closure materials such as hemostats, glues, high-strength medical adhesives, fibrin, and other sealants will negatively impact the market’s growth during the forecast horizon. Additionally, the implementation of the Patient Protection and Affordable Care Act (PPACA) in the U.S. will hamper the growth of the market in North America. There have been a number of incidences of product recalls owing to the side effects associated with some surgical devices. This will also restrain the market. The overall market has a huge scope to grow across the emerging economies in Latin America, Asia Pacific, and Eastern Europe.

In terms of product type, the report broadly segments the global surgical equipment market into surgical sutures and staples, surgical handheld instruments, and electrosurgical devices. The surgical handheld instruments segment has been further divided into forceps, scalpels, retractors, and scissors. The demand for surgical sutures and staples was the highest in 2012 and the segment accounted for over 55% of the market. However, during the forecast period, the segment is expected to lose market share to electrosurgical devices.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=183

The report studies the surgical equipment market across four key regions: North America, Europe, Asia Pacific, and Rest of the World. Presently, the overall market is dominated by Europe and North America. However, growing public investment in the healthcare sector across Latin America and Asia Pacific is expected to fuel the demand for surgical equipment.

The report profiles some of the key players in the global surgical equipment market such as Covidien plc, Ethicon Inc., B. Braun Melsungen AG, Integra LifeSciences Holdings Corporation, CONMED Corporation, CareFusion Corporation, ERBE Elektromedizin GmbH, KLS Martin LP, Medicon eG, Aspen Surgical Products Inc., and Stryker Corporation. It also provides detailed information about the key players including their product portfolio, financial overview, business strategies, and recent developments.

Big Expectations for the future of Surgical Procedures Volume Market

Rising geriatric population across the world has been identified as a major factor fueling the growth of the surgical procedures market. This is primarily due to elderly people are highly susceptible to various chronic disorders. Moreover, growth in the global population over 65 years of age would highly affect market growth. According to the U.S. Census Board, people older than 65 years represented around 13% of the total population; this percentage is expected to reach 20% by 2030. According to the World Health Organization, the global geriatric population is anticipated to reach 1.5 billion by 2050. Countries aging at a rapid pace are the U.S., Japan, and Germany. Other factors driving the surgical procedures volume globally include increasing incidence of chronic disorders and rise in the number of trauma injury cases. The surgical procedures volume market has been segmented into cardiovascular, orthopedic, neurosurgery, ophthalmic, gynecology, and other procedures such as urology and dental.

The cardiovascular procedures segment has been further categorized into cardiac rhythm management devices implantations, interventional cardiology procedures, and heart transplantation. The interventional cardiology procedures sub-segment held the largest share of the cardiovascular procedures segment due to rising usage of cardiac catheterization in structural heart disease and is becoming complex due to increase in incidence of therapeutic catheterization. According to the American Heart Association, over 5 million people in the U.S. are diagnosed with heart valve disease each year, thereby making coronary angiography the leading segment in the interventional cardiology procedures market. The neurosurgery procedures segment has been sub-segmented into craniotomy, aneurysm coil embolization, CSF drainage, and CSF shunts. CSF drainage was the largest sub-segment of the neurosurgery segment, while the craniotomy sub-segment is anticipated to grow at the fastest rate during the forecast period due to recent developments in intraoperative imaging technologies. Orthopedic procedures have been categorized into three segments: joint replacement surgery, ligament/tendon repair surgery, and spine surgery. Joint replacement was the largest sub-segment of the orthopedic procedures segment. The sub-segment is further segmented into knee replacement, hip replacement, and shoulder replacement surgery. Knee replacement surgery dominated the joint replacement surgery segment as it is considered the most effective intervention for severe osteoarthritis, reducing pain and disability, and restoring patients to near normal function. The ophthalmic procedures segment has been categorized into three sub-segments: cataract surgery, refractive surgery, and glaucoma surgery. The cataract surgery sub-segment held the largest share of the global ophthalmic procedures market and in expected to expand at the highest CAGR due to technological advances and better efficacy of the procedures. Gynecology procedures have been categorized into three segments: hysterectomy surgery, uterine artery embolization, and cesarean section surgery. The continued growth of the global gynecology procedures market is attributed to changing lifestyle, increase in per capita income in the emerging markets, and rising prevalence of gynecological diseases such as menorrhagia, uterine fibroids, and cervical cancers globally. The other procedures segment includes urology procedures and dental procedures. The dental procedures sub-segment is anticipated to witness highest growth rate during the forecast period due to technical advancements leading to higher productivity and efficacy.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1289

Asia Pacific dominated the global surgical procedures market in 2014, accounting for a share of over 30% primarily due to large patient base, increasing incidence of cardiovascular diseases, traumatic injuries, neurological disorders, and introduction of advanced surgical technologies. Increase in the geriatric population also plays a major role in the growth of the surgical procedures market. Population over 65 years of age in Asia is likely to increase dramatically by 314%, from 207 million in 2000 to 857 million in 2050. This will increase the number of surgery procedures in the region. North America was the fastest growing market for surgical procedures in terms of volume during the forecast period from 2014 to 2023, due to growing innovation and adoption of new surgical technologies, high growth of minimally invasive surgeries, and C-section surgeries. Moreover, efficient reimbursement facilities, large health care infrastructure, rise in the health care expenditure, and high number of hospital beds per capita are anticipated to accelerate the medical infrastructure development in the U.S. making it the dominating segment in North America. Europe was the second largest market for surgical procedures in terms of volume in 2014, accounting for a share of 31.1% of the global market. Primary factors driving growth in the region include increase in the geriatric population and rise in the incidence of fall injuries, traffic-related injuries, cardiovascular diseases, and orthopedic cases. According to the European Commission database, the average number of surgical procedures for cardiac disorders has increased by around 20% from 2005 to 2010. Germany held the largest share of the surgical procedures market in Europe in 2014 due to the better reimbursement mechanism. Brazil accounted for the largest share of the surgery procedures market in Latin America. Growth of the market is attributed to high prevalence of chronic diseases, rise in geriatric population, and increase in health care expenditure. Mexico is expected to be the fastest growing market in Latin America due to low cost of medical treatments and high prevalence of chronic and infectious diseases.

Key Trends Shaping the Global Cardiopulmonary Stress Testing Systems Market

The dramatic change in lifestyles marred by poor dietary intake, lack of exercise, and stressful schedules have all worked towards making the global population susceptible to obesity and related disorders. A growing consequence of this is seen in the rising number of cardiac patients, who, in turn, have increased the uptake of cardiopulmonary stress testing systems. These systems are used for evaluating the condition of the patient’s heart. According to the World Health Organization (WHO), coronary artery diseases account for 64% of overall cardiovascular deaths across the globe, which has become the primary cursor for increasing sales of cardiopulmonary stress testing systems. In a bid to help patients take well-calculated preventive measures, healthcare centers are adopting various types of cardiopulmonary stress testing systems to provide holistic health checkups.

Transparency Market Research’s recently published report states that the opportunity in the global cardiopulmonary stress testing systems will be worth US$6.67 bn by 2023 as compared to US$3.30 bn in 2014. Between 2015 and 2023, the market is expected to rise at a CAGR of 8.20%. The global market will also receive a boost from growing healthcare infrastructure in the developing countries. The increasing disposable incomes, rising awareness amongst people about cardiovascular diseases and other related conditions, and the burgeoning health insurance industry are collectively expected to provide this market an impetus.

Obesity Continues to Fuel North America Market

The North America cardiopulmonary stress testing systems market is expected to expand at a CAGR of 7.3% between 2015 and 2023. The growth in this region will be attributable to the high adoption rate of cardiac monitoring equipment such as cardiopulmonary exercise testing (CPET) systems, pulse oximeters, stress ECG, SPECT, and stress blood pressure monitors. A high incidence of cardiac disorders in the region due to rising cases of obesity are the prime reason for the remarkable growth of this regional market.

The presence of leading equipment manufacturers in the North America cardiopulmonary stress testing systems market, high awareness amongst people, and enactment of laws such as Affordable Healthcare Act have further bolstered the demand for such equipment in the recent years. The market in North America has also benefited from supportive healthcare infrastructure and introduction of innovative products with ongoing research and development activities.

Asia Pacific is anticipated to be the next big regional market in the overall cardiopulmonary stress testing systems market. The improving purchasing power of consumers, a huge population base, and growing number of patients being diagnosed with cardiovascular diseases will keep this region at the forefront of the global market in the near future.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1530

Demand for CPET Increases with Technological Advancements

Amongst the various types of products studied in the report, the cardiopulmonary exercise testing (CPET) systems are expected to see an upswing in demand. This segment includes portable CPET systems and desktop CPET systems. The critical role of this non-invasive test to ascertain pulmonary, neuropsychological, hematopoietic, cardiovascular, and skeletal muscle systems’ response to exercise has been propelling the growth of these systems. Technological advancements in this equipment to evaluate the functional parameters are anticipated to boost the market’s growth. The report states that the CPET systems segment will expand at a CAGR of 8.5% between 2015 and 2023.

Some of the leading players operating in the global cardiopulmonary stress testing systems market are Spacelabs Healthcare, GE Healthcare, Philips Healthcare, and CareFusion Corporation. Analysts state that players must look at investing in developing regions as the countries will have higher healthcare budgets in the coming years. Furthermore, companies could also benefit from the rising medical tourism industry in the emerging economies that are willing to spend on acquiring new equipment and systems.

Amylases Biofuel Enzymes Market - Latest Trends & Insights 2019

Besides the additional cost of fossil fuels, the global amylases biofuel enzymes market is projected to considerably gain from the increasing demand for energy derived from renewable resources. In a new study, titled “Amylases Biofuel Enzymes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” Transparency Market Research (TMR) presents exhaustive details pertaining to various factors encouraging or inhibiting growth of market.

Overall, the market has been treading along a positive trajectory. However, the high level of carbon emissions from machines deployed at farm plants for biofuels creates bottlenecks for the market. Stringent regulations aimed at curbing carbon emission are therefore expected to hamper the amylases biofuel enzyme producers as well.

Various types of amylase biofuels are currently available in the market, among which cellulosic ethanol is becoming increasingly popular. In addition, scientists have discovered a new enzyme called Caffeoyl shikimate esterase, which is derived from plants. Such discoveries are touted as major breakthroughs in the production of cellulosic biofuels, which are mainly obtained from plastics, chemicals, and crop waste.

Caffeoyl shikimate esterase helps controlling the formation of lignin. Downregulating its functions could reduce 36% lignin per gram of stem materials, which will subsequently boost sugar levels up by four times. The development of this enzyme is therefore expected to prompt a revolution in the amylases biofuel enzymes market.

Regionally, amylases biofuel producers have been witnessing lucrative prospects in Brazil. The country presently leads the global amylases biofuel enzymes market and is expected to continue its dominance through the forecast period between 2013 and 2019. The U.S. has also emerged as an attractive market for amylases biofuel enzymes in the last few years. Ethanol is the most commonly used biofuel additive in the country.

Companies such as Danisco-Genencor and Novozymes have been engaged in the production of enzymes for several years. Together, they account for a dominant share in the production of enzymes. Besides this, Codexis has partnered with Shell to produce enzymes for second generation biofuels. In order to gain a competitive advantage, these companies have been focusing on product development.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2430

While the amylases biofuel enzymes market is still at a nascent stage, increasing investments in research and development by the aforementioned companies will fuel its growth in the forthcoming years. Furthermore, these companies are planning to invest in the development of myriad potential feedstock to scale up their production process. This is expected to drive the market during the forecast period.

Presently, the global amylases biofuel enzymes market is exhibiting a consolidated vendor landscape. Some of the prominent companies operating in the market include Enzyme Supplies Ltd., Enzyme Solutions Inc., aEnzyme Development Corporation, Jiangsu Boli Bioproducts Co. Ltd, Novozymes A/S, Montana Microbial Products, Schaumann Bioenergy, Noor Creations, Specialty Enzymes & Biotechnologies Co., Royal Dsm Nv, and Verenium Corporation